{
    "patient": {
        "Name": "Kimberly Berry",
        "DateOfBirth": "1945-08-15",
        "Sex": "Male",
        "Diagnosis": "Small cell carcinoma",
        "BodyPart": "Prostate",
        "Physician": "Dr. Linda Phillips",
        "TreatingInstitution": "Montgomery, Lynn and Stone"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Prostate",
            "CollectedDate": "2024-04-05",
            "ReceivedDate": "2024-04-07",
            "TumorPercentage": "59%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2024-04-10",
            "ReceivedDate": "2024-04-11"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "SDHB",
                "DNA Alteration": "c.487T>C",
                "GeneMutation": "p.S163P Nonsense-LOF",
                "VariantAlleleFraction": "7.0%"
            },
            {
                "Gene": "DICER1",
                "DNA Alteration": "c.5437G>A",
                "GeneMutation": "p.E1813K Nonsense-LOF",
                "VariantAlleleFraction": "30.62%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "MUTYH",
                "DNA Alteration": "c.1014G>C",
                "GeneMutation": "p.Y1225X Spliceregionvariant-LOF",
                "VariantAlleleFraction": "4.74%"
            },
            {
                "Gene": "IDH1",
                "DNA Alteration": "c.394C>T",
                "GeneMutation": "p.E1813K Frameshift-LOF",
                "VariantAlleleFraction": "21.76%"
            },
            {
                "Gene": "CHD6",
                "DNA Alteration": "c.4800C>G",
                "GeneMutation": "p.I1600M Stopgain-LOF",
                "VariantAlleleFraction": "2.66%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "MYCN",
            "TP53",
            "ARID2",
            "ALDH2",
            "BRCA2"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "42 m/Mb",
            "Tmbpercentile": "14%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "High"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "MAP2K2",
                "DNA Alteration": "c.383C>T",
                "GeneMutation": "p.P128L Nonsense-GOF",
                "VariantAlleleFraction": "21.12%"
            },
            {
                "Gene": "MAP2K2",
                "DNA Alteration": "c.383C>T",
                "GeneMutation": "p.P128L Spliceregionvariant-GOF",
                "VariantAlleleFraction": "10.92%"
            },
            {
                "Gene": "NTRK1",
                "DNA Alteration": "c.1792C>T",
                "GeneMutation": "p.G607V Stopgain-LOF",
                "VariantAlleleFraction": "14.75%"
            },
            {
                "Gene": "CDKN2A",
                "DNA Alteration": "c.248A>C",
                "GeneMutation": "p.R80X Nonsense-GOF",
                "VariantAlleleFraction": "6.98%"
            },
            {
                "Gene": "PTPN11",
                "DNA Alteration": "c.1508G>C",
                "GeneMutation": "p.G503A Frameshift-LOF",
                "VariantAlleleFraction": "9.14%"
            },
            {
                "Gene": "SDHA",
                "DNA Alteration": "c.1660C>T",
                "GeneMutation": "p.R554W Frameshift-GOF",
                "VariantAlleleFraction": "5.11%"
            },
            {
                "Gene": "PHF6",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R225X Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "4.69%"
            },
            {
                "Gene": "SIX1",
                "DNA Alteration": "c.530A>G",
                "GeneMutation": "p.Q177R Frameshift-GOF",
                "VariantAlleleFraction": "8.84%"
            },
            {
                "Gene": "PTCH1",
                "DNA Alteration": "c.3583A>T",
                "GeneMutation": "p.T1195S Stopgain-LOF",
                "VariantAlleleFraction": "5.77%"
            }
        ],
        "Germline": []
    },
    "low coverage regions": [
        "KLF4",
        "PIK3CA",
        "SMO"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "SDHB",
                "DNA Alteration": "c.487T>C",
                "GeneMutation": "p.S163P Nonsense-LOF",
                "description": "STK11 (LKB1) encodes an enzyme in the serine/threonine kinase family that is responsible for maintaining energy metabolism and cellular polarization through the activation of AMP-activated protein kinase and other members of the AMPK family. The enzyme also acts as a tumor suppressor by regulating cell growth. Loss of function mutations, copy number loss, epigenetic variation, and underexpression of STK11 are associated with cancer progression.",
                "VariantAlleleFraction": "7.0%"
            },
            {
                "Gene": "DICER1",
                "DNA Alteration": "c.5437G>A",
                "GeneMutation": "p.E1813K Nonsense-LOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "30.62%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "MUTYH",
                "DNA Alteration": "c.1014G>C",
                "GeneMutation": "p.Y1225X Spliceregionvariant-LOF",
                "description": "KRAS is a GDP/GTP binding protein that acts as an intracellular signal transducer. KRAS is involved in several pathways involved in cellular proliferation and survival, including the PI3K-AKT-mTOR pathway and the Ras-Raf-MEK-ERK pathway. Activating mutations, copy number gains, and overexpression of KRAS are associated with cancer progression.",
                "VariantAlleleFraction": "4.74%"
            },
            {
                "Gene": "IDH1",
                "DNA Alteration": "c.394C>T",
                "GeneMutation": "p.E1813K Frameshift-LOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "21.76%"
            },
            {
                "Gene": "CHD6",
                "DNA Alteration": "c.4800C>G",
                "GeneMutation": "p.I1600M Stopgain-LOF",
                "description": "KRAS is a GDP/GTP binding protein that acts as an intracellular signal transducer. KRAS is involved in several pathways involved in cellular proliferation and survival, including the PI3K-AKT-mTOR pathway and the Ras-Raf-MEK-ERK pathway. Activating mutations, copy number gains, and overexpression of KRAS are associated with cancer progression.",
                "VariantAlleleFraction": "2.66%"
            }
        ]
    },
    "clinical history": {
        "Date": "2024-04-05"
    },
    "other": {
        "ReportId": "1616",
        "ReportDate": "2024-04-07",
        "SignedBy": "Linda Phillips",
        "Supervisor": "Dr. Jeremy Vazquez"
    }
}